Xu Zheyuan, Wang Yang, Wang Lan, Cui Fengxian, Zhang Libin, Xiong Jian, Peng Hao
Department of Thoracic Surgery, The First People's Hospital of Yunnan Province, the Affiliated Hospital of Kunming University of Science and Technology, No. 157 Jinbi Road, 650032, Kunming, Yunnan, China.
Department of Anesthesiology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No. 157 Jinbi Road, 650032, Kunming, Yunnan, China.
Hered Cancer Clin Pract. 2021 Feb 9;19(1):16. doi: 10.1186/s13053-021-00174-1.
The pathogenic BRCA1/2 germline mutations contributed to Hereditary Breast and Ovarian Cancer (HBOC) susceptibility. The features of BRCA1/2 germline mutations in non-small cell lung cancer (NSCLC) have not been systematically studied. Here we performed the first study investigating the characteristics of pathogenic BRCA1/2 germline mutations in Chinese NSCLC patients and compared them with those from Chinese HBOC.
Information on BRCA1/2 germline mutations from 9010 Chinese NSCLC patients were collected from available studies and analyzed, and compared with the BRCA1/2 germline mutations from Chinese HBOC BRCA1/2 database (LOVD database, 20,523 patients).
19 (20 carriers, 0.22 %) pathogenic BRCA1 and 60 (66 carriers, 0.73 %) pathogenic BRCA2 germline mutations from NSCLC were identified. The carrier frequency of BRCA1/2 in Chinese NSCLC patients (86/9010 = 0.95 %) was significantly lower than that in Chinese breast and ovary cancer patients (1481/20,523 = 7.2 %) (P < 0.001). We found that frameshift and nonsense mutations were the predominant types of BRCA1/2 mutation in NSCLC, with no obvious hot spot mutations. No significant difference in the ratio of frameshift and nonsense mutations was found between BRCA1 and BRCA2 in NSCLC. 5 out of 19 mutations in BRCA1 and 23 out of 60 mutations in BRCA2 were novel mutations found in NSCLC that have never been reported in Chinese HBOC. A trend of higher percentage of BRCA1 nonsense mutations in the carriers was revealed in NSCLC compared with HBOC, while no such difference was found in BRCA2 in all types of mutations.
BRCA1/2 germline mutations from NSCLC exhibited distinct characteristics compared with those from HBOC in Chinese population, including lower carrier frequency than HBOC, higher ratio of nonsense mutations and carriers than HBOC, and novel BRCA1/2 germline mutations never found in HBOC.
致病性BRCA1/2种系突变会导致遗传性乳腺癌和卵巢癌(HBOC)易感性增加。非小细胞肺癌(NSCLC)中BRCA1/2种系突变的特征尚未得到系统研究。在此,我们开展了首项研究,调查中国NSCLC患者中致病性BRCA1/2种系突变的特征,并将其与中国HBOC患者的特征进行比较。
从现有研究中收集并分析了9010例中国NSCLC患者的BRCA1/2种系突变信息,并与中国HBOC的BRCA1/2种系突变(LOVD数据库,20523例患者)进行比较。
在NSCLC中鉴定出19个(20名携带者,0.22%)致病性BRCA1种系突变和60个(66名携带者,0.73%)致病性BRCA2种系突变。中国NSCLC患者中BRCA1/2的携带频率(86/9010 = 0.95%)显著低于中国乳腺癌和卵巢癌患者(1481/20523 = 7.2%)(P < 0.001)。我们发现,移码突变和无义突变是NSCLC中BRCA1/2突变的主要类型,无明显热点突变。NSCLC中BRCA1和BRCA2的移码突变与无义突变比例无显著差异。BRCA1的19个突变中有5个以及BRCA2的60个突变中有23个是在NSCLC中发现的新突变,在中国HBOC中从未报道过。与HBOC相比,NSCLC携带者中BRCA1无义突变的比例呈现更高的趋势,而在所有类型的突变中,BRCA2未发现此类差异。
与中国人群HBOC中的BRCA1/2种系突变相比,NSCLC中的BRCA1/2种系突变表现出不同特征,包括携带频率低于HBOC、无义突变和携带者比例高于HBOC,以及在HBOC中从未发现的新BRCA1/2种系突变。